{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T22:53:53Z","timestamp":1784588033494,"version":"3.55.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-025-01716-8","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T10:26:46Z","timestamp":1744626406000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Novel CSF \u03b2-synuclein-specific assays signal early synaptic degeneration in Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"17","author":[{"given":"Sherif","family":"Bayoumy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Goossens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"De Rocker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senna Y.","family":"Sie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nolan J.","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiesje M.","family":"van der Flier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte E.","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugeen","family":"Vanmechelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge M. W.","family":"Verberk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"issue":"12","key":"1716_CR1","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/S1474-4422(07)70291-0","volume":"6","author":"S Seshadri","year":"2007","unstructured":"Seshadri S, Wolf PA. Lifetime risk of stroke and dementia: current concepts, and estimates from the Framingham Study. Lancet Neurol. 2007;6(12):1106\u201314.","journal-title":"Lancet Neurol"},{"issue":"10","key":"1716_CR2","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/j.neurobiolaging.2005.09.012","volume":"27","author":"SW Scheff","year":"2006","unstructured":"Scheff SW, Price DA, Schmitt FA, Mufson EJ. Hippocampal synaptic loss in early Alzheimer\u2019s disease and mild cognitive impairment. Neurobiol Aging. 2006;27(10):1372\u201384.","journal-title":"Neurobiol Aging"},{"key":"1716_CR3","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.neuropharm.2013.10.018","volume":"79","author":"SE Counts","year":"2014","unstructured":"Counts SE, Alldred MJ, Che S, Ginsberg SD, Mufson EJ. Synaptic gene dysregulation within hippocampal CA1 pyramidal neurons in mild cognitive impairment. Neuropharmacology. 2014;79:172\u20139.","journal-title":"Neuropharmacology"},{"key":"1716_CR4","doi-asserted-by":"crossref","unstructured":"Scheltens P, De Strooper B, Kivipelto M, Holstege H, Ch\u00e9telat G, Teunissen CE, Cummings J, van der Flier WM. Alzheimer's disease. Lancet. 2021;397(10284):1577\u201390.","DOI":"10.1016\/S0140-6736(20)32205-4"},{"issue":"1","key":"1716_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41582-022-00749-z","volume":"19","author":"M Tzioras","year":"2023","unstructured":"Tzioras M, McGeachan RI, Durrant CS, Spires-Jones TL. Synaptic degeneration in Alzheimer disease. Nat Rev Neurol. 2023;19(1):19\u201338.","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"1716_CR6","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack CR Jr, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. 2024;20(8):5143\u201369.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"1716_CR7","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/ana.410300410","volume":"30","author":"RD Terry","year":"1991","unstructured":"Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in alzheimer\u2019s disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30(4):572\u201380.","journal-title":"Ann Neurol"},{"issue":"5","key":"1716_CR8","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/ana.410270502","volume":"27","author":"ST DeKosky","year":"1990","unstructured":"DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer\u2019s disease: correlation with cognitive severity. Ann Neurol. 1990;27(5):457\u201364.","journal-title":"Ann Neurol"},{"issue":"5","key":"1716_CR9","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/BF01273157","volume":"103","author":"K Blennow","year":"1996","unstructured":"Blennow K, Bogdanovic N, Alafuzoff I, Ekman R, Davidsson P. Synaptic pathology in Alzheimer\u2019s disease: Relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele. J Neural Transm. 1996;103(5):603\u201318.","journal-title":"J Neural Transm"},{"issue":"3","key":"1716_CR10","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.neuron.2014.10.038","volume":"84","author":"R Sperling","year":"2014","unstructured":"Sperling R, Mormino E, Johnson K. The evolution of preclinical Alzheimer\u2019s disease: implications for prevention trials. Neuron. 2014;84(3):608\u201322.","journal-title":"Neuron"},{"issue":"12","key":"1716_CR11","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201911170","volume":"11","author":"S Palmqvist","year":"2019","unstructured":"Palmqvist S, Insel PS, Stomrud E, Janelidze S, Zetterberg H, Brix B, et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer\u2019s disease. EMBO Mol Med. 2019;11(12): e11170.","journal-title":"EMBO Mol Med"},{"issue":"23","key":"1716_CR12","doi-asserted-by":"publisher","first-page":"13450","DOI":"10.1073\/pnas.96.23.13450","volume":"96","author":"JE Galvin","year":"1999","unstructured":"Galvin JE, Uryu K, Lee VMY, Trojanowski JQ. Axon pathology in Parkinson\u2019s disease and Lewy body dementia hippocampus contains \u03b1-, \u03b2-, and \u03b3-synuclein. Proc Natl Acad Sci. 1999;96(23):13450\u20135.","journal-title":"Proc Natl Acad Sci"},{"issue":"1\u20132","key":"1716_CR13","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/S0006-8993(02)02643-4","volume":"941","author":"F Mori","year":"2002","unstructured":"Mori F, Tanji K, Yoshimoto M, Takahashi H, Wakabayashi K. Immunohistochemical comparison of alpha- and beta-synuclein in adult rat central nervous system. Brain Res. 2002;941(1\u20132):118\u201326.","journal-title":"Brain Res"},{"issue":"10","key":"1716_CR14","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1074\/mcp.M116.059915","volume":"15","author":"P Oeckl","year":"2016","unstructured":"Oeckl P, Metzger F, Nagl M, von Arnim CA, Halbgebauer S, Steinacker P, et al. Alpha-, Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Increased Concentrations in Alzheimer\u2019s and Creutzfeldt-Jakob Disease but No Alteration in Synucleinopathies. Mol Cell Proteomics. 2016;15(10):3126\u201338.","journal-title":"Mol Cell Proteomics"},{"issue":"3","key":"1716_CR15","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1021\/acs.jproteome.9b00824","volume":"19","author":"P Oeckl","year":"2020","unstructured":"Oeckl P, Halbgebauer S, Anderl-Straub S, von Arnim CAF, Diehl-Schmid J, Froelich L, et al. Targeted mass spectrometry suggests beta-synuclein as synaptic blood marker in Alzheimer\u2019s disease. J Proteome Res. 2020;19(3):1310\u20138.","journal-title":"J Proteome Res"},{"issue":"4","key":"1716_CR16","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1136\/jnnp-2020-324306","volume":"92","author":"S Halbgebauer","year":"2021","unstructured":"Halbgebauer S, Oeckl P, Steinacker P, Yilmazer-Hanke D, Anderl-Straub S, von Arnim C, et al. Beta-synuclein in cerebrospinal fluid as an early diagnostic marker of Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry. 2021;92(4):349\u201356.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"1716_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/ana.26360","volume":"92","author":"P Oeckl","year":"2022","unstructured":"Oeckl P, Wagemann O, Halbgebauer S, Anderl-Straub S, Nuebling G, Prix C, et al. Serum Beta-Synuclein Is Higher in Down Syndrome and Precedes Rise of pTau181. Ann Neurol. 2022;92(1):6\u201310.","journal-title":"Ann Neurol"},{"issue":"1","key":"1716_CR18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1136\/jnnp-2022-329124","volume":"94","author":"L Barba","year":"2023","unstructured":"Barba L, Abu Rumeileh S, Bellomo G, Paolini Paoletti F, Halbgebauer S, Oeckl P, et al. Cerebrospinal fluid \u03b2-synuclein as a synaptic biomarker for preclinical Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry. 2023;94(1):83\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"1716_CR19","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1002\/alz.12790","volume":"19","author":"P Oeckl","year":"2023","unstructured":"Oeckl P, Anderl-Straub S, Danek A, Diehl-Schmid J, Fassbender K, Fliessbach K, et al. Relationship of serum beta-synuclein with blood biomarkers and brain atrophy. Alzheimers Dement. 2023;19(4):1358\u201371.","journal-title":"Alzheimers Dement"},{"issue":"11","key":"1716_CR20","doi-asserted-by":"publisher","first-page":"4896","DOI":"10.1002\/alz.13046","volume":"19","author":"P Oeckl","year":"2023","unstructured":"Oeckl P, Bluma M, Bucci M, Halbgebauer S, Chiotis K, Sandebring-Matton A, et al. Blood \u03b2-synuclein is related to amyloid PET positivity in memory clinic patients. Alzheimers Dement. 2023;19(11):4896\u2013907.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1716_CR21","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3390\/biom12010142","volume":"12","author":"J Hayashi","year":"2022","unstructured":"Hayashi J, Carver JA. \u03b2-Synuclein: an enigmatic protein with diverse functionality. Biomolecules. 2022;12(1):142.","journal-title":"Biomolecules"},{"issue":"8","key":"1716_CR22","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.1002\/alz.13109","volume":"19","author":"A Pilotto","year":"2023","unstructured":"Pilotto A, Bongianni M, Tirloni C, Galli A, Padovani A, Zanusso G. CSF alpha-synuclein aggregates by seed amplification and clinical presentation of AD. Alzheimers Dement. 2023;19(8):3754\u20139.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"1716_CR23","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1002\/alz.13658","volume":"20","author":"G Bellomo","year":"2024","unstructured":"Bellomo G, Toja A, Paolini Paoletti F, Ma Y, Farris CM, Gaetani L, et al. Investigating alpha-synuclein co-pathology in Alzheimer\u2019s disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay. Alzheimers Dement. 2024;20(4):2444\u201352.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1716_CR24","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3233\/JAD-132306","volume":"41","author":"WM van der Flier","year":"2014","unstructured":"van der Flier WM, Pijnenburg YA, Prins N, Lemstra AW, Bouwman FH, Teunissen CE, et al. Optimizing patient care and research: the Amsterdam Dementia Cohort. J Alzheimers Dis. 2014;41(1):313\u201327.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"1716_CR25","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3233\/JAD-170850","volume":"62","author":"WM van der Flier","year":"2018","unstructured":"van der Flier WM, Scheltens P. Amsterdam Dementia Cohort: Performing Research to Optimize Care. J Alzheimers Dis. 2018;62(3):1091\u2013111.","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"1716_CR26","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jalz.2014.01.001","volume":"10","author":"F Jessen","year":"2014","unstructured":"Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Ch\u00e9telat G, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer\u2019s disease. Alzheimers Dement. 2014;10(6):844\u201352.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"1716_CR27","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):270\u20139.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"1716_CR28","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):263\u20139.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"1716_CR29","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","volume":"256","author":"RC Petersen","year":"2004","unstructured":"Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183\u201394.","journal-title":"J Intern Med"},{"key":"1716_CR30","doi-asserted-by":"crossref","unstructured":"Willemse EAJ, Tijms BM, van Berckel BNM, Le Bastard N, van der Flier WM, Scheltens P, Teunissen CE. Comparing CSF amyloid-beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2021;13(1):e12182.","DOI":"10.1002\/dad2.12182"},{"key":"1716_CR31","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.dadm.2018.08.006","volume":"10","author":"EAJ Willemse","year":"2018","unstructured":"Willemse EAJ, van Maurik IS, Tijms BM, Bouwman FH, Franke A, Hubeek I, et al. Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer\u2019s disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project. Alzheimers Dement (Amst). 2018;10:563\u201372.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"22","key":"1716_CR32","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1212\/WNL.0b013e3181c47cc2","volume":"73","author":"CE Teunissen","year":"2009","unstructured":"Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, Comabella M, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology. 2009;73(22):1914\u201322.","journal-title":"Neurology"},{"key":"1716_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/978-1-4939-9706-0_2","volume":"2044","author":"AHYS Hok","year":"2019","unstructured":"Hok AHYS, Willemse EAJ, Teunissen CE, Del Campo M. Guidelines for CSF Processing and Biobanking: Impact on the Identification and Development of Optimal CSF Protein Biomarkers. Methods Mol Biol. 2019;2044:27\u201350.","journal-title":"Methods Mol Biol"},{"issue":"1","key":"1716_CR34","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ab.2011.06.002","volume":"417","author":"JP Langedijk","year":"2011","unstructured":"Langedijk JP, Zekveld MJ, Ruiter M, Corti D, Back JW. Helical peptide arrays for lead identification and interaction site mapping. Anal Biochem. 2011;417(1):149\u201355.","journal-title":"Anal Biochem"},{"key":"1716_CR35","doi-asserted-by":"crossref","unstructured":"Andreasson U, Perret-Liaudet A, van Waalwijk van Doorn LJC, Blennow K, Chiasserini D, Engelborghs S, et al. A practical guide to immunoassay method validation. Front Neurol. 2015;6:179.","DOI":"10.3389\/fneur.2015.00179"},{"issue":"3","key":"1716_CR36","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837\u201345.","journal-title":"Biometrics"},{"issue":"1","key":"1716_CR37","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","volume":"3","author":"WJ Youden","year":"1950","unstructured":"Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32\u20135.","journal-title":"Cancer"},{"issue":"1","key":"1716_CR38","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1093\/brain\/awaa395","volume":"144","author":"JB Pereira","year":"2021","unstructured":"Pereira JB, Janelidze S, Ossenkoppele R, Kvartsberg H, Brinkmalm A, Mattsson-Carlgren N, et al. Untangling the association of amyloid-\u03b2 and tau with synaptic and axonal loss in Alzheimer\u2019s disease. Brain. 2021;144(1):310\u201324.","journal-title":"Brain"},{"key":"1716_CR39","doi-asserted-by":"crossref","unstructured":"Das S, Goossens J, Jacobs D, Dewit N, Pijnenburg YAL, In 't Veld S, et al. Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer's disease and frontotemporal dementia. Alzheimers Res Ther. 2023;15(1):62.","DOI":"10.1186\/s13195-023-01212-x"},{"issue":"6","key":"1716_CR40","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.jalz.2015.12.005","volume":"12","author":"MC de Wilde","year":"2016","unstructured":"de Wilde MC, Overk CR, Sijben JW, Masliah E. Meta-analysis of synaptic pathology in Alzheimer\u2019s disease reveals selective molecular vesicular machinery vulnerability. Alzheimers Dement. 2016;12(6):633\u201344.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"1716_CR41","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"1716_CR42","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000112832","volume":"5","author":"R Barbour","year":"2008","unstructured":"Barbour R, Kling K, Anderson JP, Banducci K, Cole T, Diep L, et al. Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis. 2008;5(2):55\u20139.","journal-title":"Neurodegener Dis"},{"issue":"5","key":"1716_CR43","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1002\/alz.12809","volume":"19","author":"J Nilsson","year":"2023","unstructured":"Nilsson J, Cousins KAQ, Gobom J, Portelius E, Chen-Plotkin A, Shaw LM, et al. Cerebrospinal fluid biomarker panel of synaptic dysfunction in Alzheimer\u2019s disease and other neurodegenerative disorders. Alzheimers Dement. 2023;19(5):1775\u201384.","journal-title":"Alzheimers Dement"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01716-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-025-01716-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01716-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T10:26:49Z","timestamp":1744626409000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-025-01716-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1716"],"URL":"https:\/\/doi.org\/10.1186\/s13195-025-01716-8","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,14]]},"assertion":[{"value":"14 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures involving human subjects were performed following the Helsinki Declaration of 1975. All participants provided written informed consent for the use of medical data and biomaterials for research purposes. The study was approved by the local Ethics Committee (2023.0759; Amsterdam UMC VUmc medical ethical committee).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Julie Goossens and Charlotte De Rocker are employees of ADx NeuroSciences NV. Eugeen Vanmechelen is a cofounder of ADx NeuroSciences. Wiesje van der Flier has conducted research programs funded by ZonMW, Nederlandse Organisatie voor Wetenschappelijk Onderzoek, European Union\u2013Seventh Framework Programme, European Joint Programme on Neurodegenerative Diseases, Alzheimer Nederland, Hersenstichting CardioVascular Onderzoek Nederland, Health\u223cHolland, Topsector Life Sciences & Health, Stichting Dioraphte, Gieskes-Strijbis Fonds, Stichting Equilibrio, Edwin Bouw Fonds, Pasman Stichting, Alzheimer & Neuropsychiatrie Foundation, Philips, Biogen MA, Amprion, Novartis-NL, Life Molecular Imaging, Avid, Roche, Fujifilm, Eisai, and Combinostics. WMvdF holds the Pasman chair; and is a recipient of ABOARD, which is a public\u2013private partnership receiving funding from ZonMW (#73305095007) and Health\u223cHolland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). All funding is paid to her institution; WMvdF is a recipient of TAP-dementia, receiving funding from ZonMw (#10510032120003) in the context of the Onderzoeksprogramma Dementie, part of the Dutch National Dementia Strategy; Gieskes Strijbis Fonds also contributes to TAP-dementia. WMvdF is a consultant for the Oxford Health Policy Forum Community Interest Company, Roche, Eisai, and Biogen MA; has been an invited speaker at Boehringer Ingelheim, Biogen MA, Danone, Eisai, WebMD Neurology (Medscape), NovoNordisk, Springer Healthcare, and the European Brain Council; and has participated in advisory boards for Biogen MA, Roche, and Eli Lilly. FV has served as a consultant for Biogen (payment to Maastricht University). Charlotte E. Teunissen is a recipient of ABOARD, and Health\u223cHolland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). CT is also a contract researcher for ADx Neurosciences, AC-Immune, Aribio, Axon Neurosciences, Beckman-Coulter, BioConnect, Bioorchestra, Brainstorm Therapeutics, Celgene, Cognition Therapeutics, EIP Pharma, Eisai, Eli Lilly, Fujirebio, Grifols, Instant Nano Biosensors, Merck, Novo Nordisk, Olink, PeopleBio, Quanterix, Roche, Siemens, Toyama, Vivoryon, and the European Commission. CT has received payments or honoraria from Eli Lilly, Grifols, Novo Nordisk, Olink, and Roche, where all payments were made to her institution. CT also serves on the editorial boards of Medidact Neurologie\/Springer and on Neurology: Neuroimmunology & Neuroinflammation. CT is the editor of Alzheimer Research and Therapy. Inge M.W. Verberk is a recipient of grants from Amsterdam UMC and Health\u2009~\u2009Holland. All the other authors report no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"81"}}